home / stock / rnxt / rnxt news

RNXT News and Press, RenovoRx Inc.

Stock Information
Company Name: RenovoRx Inc.
Stock Symbol: RNXT
Market: NASDAQ
Website: renovorx.com
Menu
RNXT RNXT Quote RNXT Short RNXT News RNXT Articles RNXT Message Board
Get RNXT Alerts

News, Short Squeeze, Breakout and More Instantly...
RNXT - RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Positio...
RNXT - RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared dru...

RNXT - RenovoRx Establishes RenovoCath® Medical Advisory Board

MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-de...

RNXT - RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-...
RNXT - RenovoRx Announces Clinical Data Supporting the TAMP(TM) Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared dru...

RNXT - $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com  News Commentary VANCOUVER, BC , Jan. 30, 2026 /CNW/ -- The global oncology sector is rocketing toward $668 bi...

RNXT - RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared dru...
RNXT - RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number ...

RNXT - RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT)  (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared d...

RNXT - The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramb...
Next 10